SCHEDULE: RA Capital Trims VOR Biopharma Stake to 17.3%

RA Capital Management and its affiliates reported a reduction in their beneficial ownership of VOR Biopharma Inc. common stock to 17.3% through recent open market sales.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") filed an Amendment No. 8 to their Schedule 13D.
• The Reporting Persons collectively beneficially own 1,186,500 shares of VOR Biopharma Inc. common stock, representing 17.3% of the outstanding class.
• This percentage is based on 6,853,907 shares of common stock outstanding as of September 18, 2025.
• RA Capital Healthcare Fund, L.P. directly holds 1,180,060 shares of common stock.
• The Fund also holds Common Stock Warrants exercisable for up to 1,056,072 shares and Pre-Funded Warrants exercisable for up to 10,000,000 shares, but these are subject to a 9.99% beneficial ownership blocker.
• Vested stock options held by Joshua Resnick (6,190 shares) and Sarah Reed (83 vested, 167 vesting within 60 days) for the benefit of RA Capital are also included in the beneficial ownership calculation.
• The Fund engaged in open market sales of VOR Biopharma common stock on multiple dates in October 2025, totaling 246,193 shares.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant institutional investor reducing its stake in the company through open market sales. While not a complete exit, it signals a partial divestment which can be perceived as a lack of conviction or a strategic reallocation of capital.

Negatives

• RA Capital Healthcare Fund, L.P., a significant institutional investor, sold a total of 246,193 shares of VOR Biopharma common stock in open market transactions between October 21, 2025, and October 27, 2025.
• The sales occurred at weighted average prices ranging from $28.01 to $28.12 per share, indicating a reduction in exposure by a major holder.

Risks

• The reduction in beneficial ownership by a significant institutional investor like RA Capital could be perceived negatively by the market, potentially signaling a lack of confidence or a reallocation of capital.
• The existence of 'Beneficial Ownership Blockers' on warrants, preventing exercise if ownership exceeds 9.99%, limits the ability of the Fund to increase its stake significantly through these instruments, which could impact future capital deployment strategies.

Future Outlook

The filing does not provide any forward-looking statements or guidance from VOR Biopharma Inc. or the Reporting Persons regarding the company's future performance or strategic direction. It solely reports changes in beneficial ownership.

Industry Context

This filing reflects a reduction in a significant institutional investor's stake in a biopharma company. Such actions can be influenced by various factors, including portfolio rebalancing, changes in investment thesis, or perceived shifts in market conditions or company prospects within the highly dynamic biotechnology sector. While not explicitly stated, a reduction in a major holder's position can sometimes precede or coincide with broader industry trends of capital reallocation or increased scrutiny on valuations.

Comparison to Industry Standards

• This Schedule 13D/A filing primarily reports changes in beneficial ownership by an institutional investor and does not contain specific operational or financial results of VOR Biopharma Inc. that would allow for a direct comparison to industry benchmarks or specific comparable companies/projects.
• The reported sales by RA Capital are a specific investment decision by one fund and do not inherently reflect broader industry-wide investment trends without further context.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on the stock price due to the selling activity of a major institutional investor.
• Potential Investors: May view the reduction in stake by RA Capital as a cautionary signal, influencing their investment decisions.

Key Dates

Recommendation

The reduction in stake by a prominent institutional investor like RA Capital Management, L.P. through open market sales is a strong negative signal. While the reasons for selling are not disclosed, such an action by a sophisticated investor often suggests a re-evaluation of the company's prospects or a strategic shift away from the investment. This could lead to increased selling pressure and a decline in investor confidence, making a 'sell' recommendation prudent for investors seeking to mitigate potential downside risk.

Keywords

VOR Biopharma, RA Capital Management, Beneficial Ownership, Schedule 13D, Stock Sales, Institutional Investor, Common Stock, Warrants, Biopharma